WeVote

Bill

Bill

LD 765

An Act To Amend The Laws Governing The Controlled Substances Prescription Monitoring Program

132nd Legislature (2025-2026) Introduced by Michele Meyer

Maine law signed to amend prescription drug monitoring program rules, affecting how controlled substances prescriptions are tracked and managed statewide.

Signed by Governor
0
WeVote Research Nonpartisan
Bill Summary · LD 765

Legislative bill overview

LD 765 amends Maine's Controlled Substances Prescription Monitoring Program (PMP) to modify how the state tracks and manages prescription opioids and other controlled substances. The bill has been signed into law as of April 22, 2025, and makes structural or operational changes to the existing prescription monitoring framework that healthcare providers and pharmacists must follow.

Why is this important

Prescription monitoring programs are critical public health tools designed to prevent prescription drug abuse, reduce opioid misuse, and identify patients seeking medications from multiple providers. Changes to Maine's PMP directly affect how effectively the state can combat prescription drug addiction and overdose deaths while balancing legitimate patient access to necessary medications.

Potential points of contention

  • Provider burden vs. public health: Amendments may increase reporting requirements or compliance obligations for pharmacies and physicians, raising concerns about administrative costs versus abuse prevention benefits
  • Patient privacy and data access: Modifications to PMP data-sharing protocols could affect which healthcare providers can access patient prescription histories, balancing law enforcement needs with privacy protections
  • Opioid prescribing standards: Changes may establish new restrictions or guidelines on opioid prescriptions, potentially affecting pain management practices and patients with legitimate chronic pain conditions

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.